Bookmark Icon
Print Icon
Email Icon
Dr. Ran Reshef
Ran Reshef, <span>MD</span>

Ran Reshef, MD

Hematology/Oncology
Blood and Marrow Stem Cell Transplantation
Languages: Hebrew
Office Phone: (212) 305-5098

Biography

Dr. Reshef trained in Hematology, Oncology and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is the Clinical Lead for the CAR-T Cell Program at Columbia, a principal investigator at the Columbia Center for Translational Immunology and a member of the Herbert Irving Comprehensive Cancer Center.

Dr. Reshef serves as Director of Translational Research for the Blood and Marrow Transplantation program and Clinical Lead for the CAR-T Cell Program. He joined Columbia University in 2015 after spending 8 years at the University of Pennsylvania where he conducted research in stem-cell transplantation and immunotherapy. Dr. Reshef primarily cares for patients with leukemia, MDS, lymphoma, myeloma and other blood cancers and he oversees the clinical trials offered to patients undergoing stem-cell transplantation. His research focuses on innovative ways to improve the outcome of patients undergoing stem-cell transplants and novel cell therapies. Dr. Reshef's research is funded by the National Cancer Institute, American Society of Clinical Oncology, National Marrow Donor Program and Department of Defense. He previously received awards from the Leukemia & Lymphoma Society and American Society of Hematology.

Area of Expertise

Please contact the doctor's office to verify that your insurance is accepted.

Education

MD, Medicine, Sackler School of Medicine, Tel Aviv University (Israel)

MSc, Translational Research, Perelman School of Medicine University of Pennsylvania

Internship: Tel Aviv Sourasky Medical Center, Israel

Residency: Tel Aviv Sourasky Medical Center, Israel

Fellowship: Perelman School of Medicine University of Pennsylvania

Publications

  1. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta, SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie J, Vonderheide RH, Porter DL (2012). “Effect of Blocking Lymphocyte Chemotaxis on Visceral Graft-vs-Host Disease.” N Engl J Med 367:135-145
  2. Reshef R, Huffman AP, Gao A, Luskin MR, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Nasta SD, Gill SI, Sell M, Kambayashi T, Richman LP, Vonderheide RH, Mick R, Porter DL (2015). “High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection In Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning” J Clin Oncol 33:2392-2398.
  3. Ryan H. Moy, Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Ximi K. Wang, James A. Hoxie, Rosemarie Mick, Stephen G. Emerson, Yi Zhang, Robert H. Vonderheide, David L. Porter and Ran Reshef (2017) "Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis" Blood 129:906-916
  4. Mishkin AD, Mapara MY, Reshef R (2018). “Iatrogenic Infertility After Curative Stem Cell Transplantation in Sickle Cell Disease Patients”. Ann Intern Med 2018 Jun 19;168(12):881-88

Herbert Irving Pavilion

161 Fort Washington Avenue
New York, NY 10032

Phone: (212) 305-5098

Fax: (212) 305-8111

Get Directions


Associate Professor of Medicine at CUMC

  • Sternberg Research Award, Abramson Cancer Center, University of Pennsylvania (2008)
  • Bradley Fellow Research Award, Department of Medicine, University of Pennsylvania (2011)
  • Austrian Junior Faculty Award, Department of Medicine, University of Pennsylvania (2012)
  • Amy Strelzer Manasevit Award for the Study of Post-Transplant Complications, National Marrow Donor Program (2013)

Transit Advisory Notice

Starting Jan. 5, 2019, 1 trains will bypass the 168th Street subway station at NewYork-Presbyterian/Columbia University Irving Medical Center until early 2020.